Differential effects of tenidap on the zymosan- and lipopolysaccharide-induced expression of mRNA for proinflammatory cytokines in macrophages

Biochemical Pharmacology

Volumn 52, Issue 1, 1996, Pages 35-42

  Bondeson, Jan ^a   Sundler, Roger ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Interleukin 1; Prostaglandin E2; Tenidap; Tumor Necrosis factor

Indexed keywords

ANTIRHEUMATIC AGENT; CALCIMYCIN; CYTOKINE; INTERLEUKIN 1; LIPOPOLYSACCHARIDE; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHOPROTEIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN; TENIDAP; TUMOR NECROSIS FACTOR ALPHA; ZYMOSAN;

ANIMAL CELL; ARACHIDONIC ACID METABOLISM; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; FEMALE; GENE EXPRESSION; INFLAMMATION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BASE SEQUENCE; CALCIMYCIN; ENZYME ACTIVATION; FEMALE; INDOLES; INTERLEUKIN-1; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDE PROBES; PHOSPHORYLATION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; ZYMOSAN;

EID: 0029889270     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00136-0     Document Type: Article

References (28)

1. Breedveld F. Tenidap: a novel cytokine-modulating antirheumatic drug for the treatment of rheumatoid arthritis. Scand J Rheumatol 23(Suppl 100): 31-44, 1994.
2. 4 and prostanoid synthesis in human polymorphonuclear leukocytes in vitro. Eicosanoids 1: 35-39, 1988.
3. Blackburn WD Jr, Heck LW, Loose LD, Eskra JD, Carry TJ. Inhibition of 5-lipoxygenase product formation and polymorphonuclear cell degranulation by tenidap sodium in patients with rheumatoid arthritis. Arthritis Rheum 34: 204-210, 1991.
4. Smith DM, Johnson JA, Loeser R, Turner RA. Evaluation of tenidap (CP-66,248) on human neutrophil arachidonic acid metabolism, chemotactic potential and clinical efficacy in the treatment of rheumatoid arthritis. Agents Action 31: 102-109, 1990.
5. 2 and subsequent eicosanoid formation in macrophages. Biochem Pharmacol 48: 1171-1179, 1994.
6. Otterness IG, Pazoles PP, Moore PF, Pepys MB. C-reactive protein as an index of disease activity. Comparison of tenidap, cyclophosphamide and dexamethasone in rat adjuvant arthritis. J Rheumatol 18: 505-511, 1991.
7. Loose LD, Sipe JD, Kirby DS, Kraska AR, Weiner ES, Shanahan WR, Leeming MRG, Farrow P, Stack CB, Ting L. Reduction of acute-phase proteins with tenidap sodium, a cytokine-modulating anti-rheumatic drug. Br J Rheumatol 32(Suppl 3): 19-25, 1993.
8. Otterness IG, Golden HW, Kadin SB. Tenidap: A new drug for arthritis. In Therapeutic Approaches to Inflammatory Diseases, Lewis AJ, Doherty NS, Ackerman NR, Eds., pp 229-241. Elsevier Science Publ., 1989.
9. Blackburn WD Jr, Loose HD, Heck LW, Chatham WW. Tenidap, in contrast to several available nonsteroidal antiinflammatory drugs, potently inhibits the release of activated neutrophil collagenase. Arthritis Rheum 34: 211-216, 1991.
10. Cleveland PL, Millard PJ, Showell HJ, Fewtrell CMS. Tenidap: a novel inhibitor of calcium influx in a mast cell line. Cell Calcium 14: 1-16, 1993.
11. McNiff P, Svensson L, Pazoles CJ, Gabel CA. Tenidap modulates cytoplasmic pH and inhibits anion transport in vitro. I. Mechanism and evidence of functional significance. J Immunol 153: 2180-2193, 1994.
12. Otterness IG, Bliven ML, Downs JT, Natoli EJ, Hanson DC. Inhibition of interleukin 1 synthesis by tenidap: a new drug for arthritis. Cytokine 3: 277-283, 1991.
13. Sipe JD, Bartle LM, Loose LD. Modification of proinflammatory cytokine production by antirheumatic agents tenidap and naproxen. J Immunol 148: 480-484, 1992.
14. Laliberte R, Perregaux D, Svensson L, Pazoles CJ, Gabel CA. Tenidap modulates cytoplasmic pH and inhibits anion transport in vitro. II. Inhibition of IL-1β production from ATP-treated monocytes and macrophages. J Immunol 153: 2168-2179, 1994.
15. Svensson U, Holst E, Sundler R. Cyclosporin-sensitive expression of cytokine mRNA in mouse macrophages responding to bacteria. Molec Immunol 32: 157-165, 1995.
16. Chomzynski P, Sacchi N. Single-step method of RNA isolation by acid guadinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
17. 2. Biochem Biophys Res Commun 137: 404-410, 1986.
18. 2 regulates macrophage-derived tumor necrosis factor gene expression. J Biol Chem 263: 5380-5384, 1988.
19. Olivera DL, Laydon JT, Hillegass L, Badger AM, Lee JC. Effects of pyridinyl imidazole compounds on murine TNF-α production. Agents Action 39 (Spec. Issue): C55-C57, 1993.
20. Griswold DE, Hillegass LM, Breton JJ, Esser KM, Adams JL. Differentiation in vivo of classical non-steroidal antiinflammatory drugs from cytokine suppressive antiinflammatory drugs and other pharmacological classes using mouse tumour necrosis factor alpha production. Drugs Exp Clin Res 19: 243-248, 1993.
21. Shakhov AN, Collart MA, Vassalli P, Nedospasov SA, Jongeneel CV. κB-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor α gene in primary macrophages. J Exp Med 171: 35-47, 1990.
22. Drouet C, Shakhov AN, Jongeneel CV. Enhancers and transcription factors controlling the inducability of the tumor necrosis factor-α promoter in primary macrophages. J Immunol 147: 1694-1700, 1991.
23. Kelly KA, Hill MR, Youkhana K, Wanker F, Gimble JM. Dimethyl sulfoxide modulated NF-κB and cytokine activation in lipopolysaccharide-treated murine macrophages. Infect Immun 62: 3122-3128, 1994.
24. Hiscott J, Marois J, Garoufalis J, d'Addario M, Roulston A, Kwan I, Pepin N, Lacoste J, Nguyen H, Bensi G, Fenton M. Characterization of a functional NF-κ B site in the human interleukin 1β promoter: evidence for a positive autoregulatory loop. Mol Cell Biol 13: 6231-6240, 1993.
25. Cogswell JP, Godlewski MM, Wisely GB, Clay WC, Leenitzer LM, Ways JP, Gray JG. NF-κB redulates IL-1β transcription through a consensus NF-κB binding site and a nonconsensus CRE-like site. J Immunol 153: 712-723, 1994.
26. Rao A. NFATp: a transcription factor required for the coordinate induction of several cytokine genes. Immunol Today 15: 274-281, 1994.
27. Bondeson J. Effects of tenidap on intracellular signal transduction and the induction of proinflammatory cytokines. A review. Gen Pharmacol (in press).
28. Littman BH, Drury CE, Zimmerer RO, Stack CB, Law CG. Rheumatoid arthritis treated with tenidap and piroxicam. Clinical associations with cytokine modulation by tenidap. Arthritis Rheum 38: 29-37, 1995.